Welcome to our dedicated page for Kineta SEC filings (Ticker: KA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Kineta’s filings can feel like parsing a clinical protocol. Phase 1 data tables, milestone-based royalty clauses, and frequent at-the-market equity raises hide in hundreds of pages. If you are hunting for a single sentence on cash runway or the latest VISTA trial update, the raw SEC PDF is a maze.
Stock Titan ends that search frustration. Our AI breaks down every document—from a Kineta quarterly earnings report 10-Q filing to the smallest 8-K—into plain-language highlights. Want instant alerts when a director buys shares? The Kineta Form 4 insider transactions real-time feed is ready. Need the risk-factor redlines in the Kineta annual report 10-K simplified? They are one click away. Even complex 14A tables on Kineta proxy statement executive compensation are summarized so you know exactly how milestones affect bonuses.
Here is what you can do:
- Track Kineta insider trading Form 4 transactions before catalysts hit.
- Dive into Kineta earnings report filing analysis to watch R&D spend versus cash on hand.
- See every Kineta 8-K material events explained, including clinical holds or new licensing deals.
- Use our dashboards for understanding Kineta SEC documents with AI—no biostatistics degree needed.
Because our system refreshes the moment EDGAR posts, you never miss a disclosure. Whether you monitor Kineta executive stock transactions Form 4 or simply need Kineta SEC filings explained simply, the answers arrive faster than the next press release.
Kineta (KA) filed a Form 4 disclosing that director Shawn Iadonato exercised 237,500 stock options on 06/23/2025 at strike prices of $0.36 and $0.611, actions triggered by full vesting upon shareholder approval of the TuHURA Biosciences merger.
To cover taxes, 52,353 shares were sold at $0.26 (Code F). Net of the sale, his direct holdings rose to 860,377 shares; combined with 8,553 shares held via an IRA, total beneficial ownership is 868,930 shares, a ~27% increase.
The transactions were contractual (Code M) rather than open-market purchases, signalling alignment but offering limited insight into insider sentiment.
Kineta Director Kimberlee C. Drapkin reported multiple securities transactions on Form 4, detailing changes in beneficial ownership on June 23-25, 2025:
- Exercised 12,500 stock options at $0.611 per share on June 23
- Disposed of 4,706 common shares at $0.26 per share through tax withholding (Form F)
- Received 6,000 new shares as an award on June 25 at $0 cost
The transactions were executed following the approval of a merger agreement between Kineta and TuHURA Biosciences at a Special Meeting of Stockholders on June 23, 2025. Per the Optionholder Treatment Agreement dated June 16, 2025, and merger agreement dated December 11, 2024 (amended May 5, 2025), the reporting person's options under the 2022 Equity Incentive Plan became fully vested. Following all transactions, Drapkin directly owns 13,794 common shares with no remaining stock options.
Director Richard Peters of Kineta reported multiple transactions on June 23-25, 2025:
- Exercised 12,500 stock options at $0.611 per share on June 23
- Disposed of 4,706 shares at $0.26 per share through share withholding (F code)
- Received 6,000 shares as a new grant on June 25 at $0 cost
The transactions were part of a broader corporate event involving a merger agreement between Kineta and TuHURA Biosciences. Per the Optionholder Treatment Agreement dated June 16, 2025, and following stockholder approval on June 23, 2025, Peters' options under the 2022 Equity Incentive Plan became fully vested.
Following these transactions, Peters directly owns 101,891 shares of Kineta common stock. The option exercise eliminated his remaining derivative securities position.
Director Marion R. Foote of Kineta reported multiple transactions on June 23-25, 2025:
- Exercised 12,500 stock options at $0.611 per share
- Disposed of 4,706 shares at $0.26 per share through tax withholding (F code)
- Received 6,000 shares as new grant at $0 cost
These transactions were part of changes related to the merger agreement between Kineta and TuHURA Biosciences. Per the Optionholder Treatment Agreement dated June 16, 2025, and following stockholder approval on June 23, 2025, the director's options under the 2022 Equity Incentive Plan became fully vested.
Following all transactions, Foote directly owns 165,156 shares of Kineta common stock. The exercised stock options, which had an expiration date of September 3, 2034, have been fully utilized, leaving a balance of 0 derivative securities.
Director Scott J. Dylla of Kineta reported multiple transactions on June 23-25, 2025:
- Exercised 12,500 stock options at $0.611 per share
- Disposed of 4,706 shares at $0.26 per share through tax withholding (F code)
- Received 6,000 new shares as a grant on June 25 at $0 cost
These transactions occurred in connection with the merger agreement between Kineta and TuHURA Biosciences. Per the Optionholder Treatment Agreement dated June 16, 2025, and the merger agreement from December 11, 2024 (amended May 5, 2025), Dylla's options under the 2022 Equity Incentive Plan became fully vested on June 23, 2025. Following all transactions, Dylla directly owns 17,794 shares and retains 12,500 stock options exercisable until September 2034.
Director David Arkowitz of Kineta reported multiple transactions on June 23-25, 2025:
- Exercised 12,500 stock options at $0.611 per share through conversion (M)
- Disposed of 4,706 shares at $0.26 per share through tax withholding (F)
- Received 6,000 new shares as an award (A) at $0
These transactions were executed following the approval of a merger agreement between Kineta and TuHURA Biosciences at a Special Meeting of Stockholders on June 23, 2025. The merger agreement triggered full vesting of options granted under the 2022 Equity Incentive Plan. Following all transactions, Arkowitz directly owns 18,141 shares of common stock.
The transactions reflect significant insider activity coinciding with the company's merger approval, with the director both exercising options and receiving new equity compensation.
Craig W. Philips, President and Secretary of Kineta, reported multiple securities transactions on June 23-25, 2025:
- Exercised 225,000 stock options at $0.36 per share on June 23
- Disposed of 47,647 shares at $0.26 per share through tax withholding (Form F)
- Acquired 60,300 new shares on June 25 at $0 cost
These transactions occurred following the approval of a merger agreement between Kineta and TuHURA Biosciences at a Special Meeting of Stockholders on June 23, 2025. The merger agreement triggered full vesting of Philips' options under the 2022 Equity Incentive Plan.
Post-transactions, Philips directly owns 298,464 shares and indirectly controls 34,654 shares through Whetstone Ventures LLC, where he serves as member manager with shared voting and dispositive power.
Thierry Guillaudeux, Chief Scientific Officer of Kineta, reported multiple securities transactions on June 23-25, 2025:
- Exercised 225,000 stock options at $0.36 per share on June 23
- Disposed of 47,647 shares at $0.26 per share through tax withholding (Form F)
- Received 23,100 new shares on June 25 at $0 cost
These transactions occurred in connection with the merger agreement between Kineta and TuHURA Biosciences. Per the Optionholder Treatment Agreement dated June 16, 2025, and the merger agreement dated December 11, 2024 (amended May 5, 2025), Guillaudeux's options under the 2022 Equity Incentive Plan became fully vested on June 23, 2025. Following all transactions, Guillaudeux directly owns 217,333 shares of common stock.
Kineta Director Raymond J. Bartoszek reported multiple stock transactions on June 23-25, 2025:
- Exercised 12,500 stock options at $0.611 per share
- Disposed of 4,706 shares at $0.26 per share through tax withholding (F)
- Received 6,000 new shares as a grant on June 25
Following these transactions, Bartoszek directly owns 31,000 shares and indirectly controls 1,750,474 additional shares through: RLB Holdings Connecticut LLC (1,748,473 shares), his son (1,001 shares), and daughter (1,000 shares). The stock option exercise was triggered by an Optionholder Treatment Agreement dated June 16, 2025, related to a merger agreement between Kineta and TuHURA Biosciences. The options, granted under the 2022 Equity Incentive Plan, became fully vested on June 23, 2025.
FAQ
What is the current stock price of Kineta (KA)?
What is the market cap of Kineta (KA)?
What is Kineta, Inc. focused on?
What therapeutic candidates are in Kineta's pipeline?
How does Kineta address the challenges of cancer treatment?
What kind of clinical trials is Kineta involved in?
What role do strategic partnerships play in Kineta's business model?
How does Kineta differentiate its immunotherapies?
What expertise does Kineta bring to the field of immuno-oncology?
How does Kineta ensure the quality and safety of its drug candidates?
